Tech Company Financing Transactions
Entos Pharmaceuticals Funding Round
Entos Pharmaceuticals, based in Edmonton, AB, secured funding from CureDuchenne Ventures.
Transaction Overview
Company Name
Announced On
5/22/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10230 Jasper Avenue 4550
Edmonton, AB, T5J 4P6
Canada
Edmonton, AB, T5J 4P6
Canada
Phone
Website
Email Address
Overview
Entos is committed to using its Fusogenix� PLV� technology to develop cures and improve the lives of patients and their families.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Lewis
Browse more venture capital transactions:
Prev: 5/22/2025: Tamtam venture capital transaction
Next: 5/22/2025: Emerge Tech venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs